Randomized phase II trial on mitomycin-C/cisplatin +/- KLT in heavily pretreated advanced breast cancer

The American Journal of Chinese Medicine
H Y GuoX C Hu

Abstract

A randomized phase II study using mitomycin (MMC)/cisplatin (DDP) regimen with or without Kanglaite (KLT, a traditional Chinese medicine) as salvage treatment was conducted to exploit KLT's potential effects on patients with advanced breast cancer (ABC). Triweekly regimen consisted of mitomycin (8 mg/m(2)) administered intravenously on day 1, and cisplatin (25 mg/m(2)) intravenously on days 1 to 3. KLT (100 ml) was given intravenously per day on days 1 to 14 every 3 weeks. Between April 2006 and July 2007, 60 patients with a median age of 48 years were randomized into MMC/DDP with or without KLT treatment. In all, the objective response rate (ORR) was 17.5%. There were no significant differences between experimental and control treatments in terms of ORR (14.3% vs. 20.7%, p = 0.730), clinical benefit rates (24.1% vs. 28.6%, p = 0.468), median time to progression (TTP; 3.63 vs. 4.0, p = 0.872), and overall survival (OS; 7.17 vs. not reached, p = 0.120). The median TTP for patients with complete or partial responses was 6.0 months, but only 2.1 months for patients with stable or progressive disease (SD or PD; p = 0.028). While the median OS for patients who obtained clinical benefit from chemotherapy was not reached, that of pati...Continue Reading

References

Dec 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G W SledgeL H Einhorn
Jan 1, 1981·Cancer·A B MillerA Winkler
Mar 27, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D MavroudisV Georgoulias
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M H CullenR L Souhami
Mar 10, 2001·Cancer Treatment Reviews·W T Bradner
Aug 31, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H C WagenaarJ B Vermorken
May 2, 2003·Seminars in Oncology·Andrew D Seidman
Jul 26, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P ReichardtH J Lück
Jan 27, 2004·Advanced Drug Delivery Reviews·G M SteilK Rebrin
Apr 20, 2004·Anti-cancer Drugs·Ornella GarroneMarco Merlano
Apr 28, 2004·Breast Cancer Research and Treatment·Yong CuiWei Zheng
Jul 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezGabriel N Hortobagyi
Jan 6, 2012·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Mia M GaudetSusan M Gapstur

❮ Previous
Next ❯

Citations

Oct 20, 2009·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Chong-Zhi WangChun-Su Yuan
Aug 21, 2013·Evidence-based Complementary and Alternative Medicine : ECAM·Shu-Yi YinNing-Sun Yang
Jul 10, 2014·BMC Complementary and Alternative Medicine·Ying LiuShi Liu
Feb 18, 2009·The American Journal of Chinese Medicine·Hyo Jeong LeeJunxuan Lü
Dec 17, 2015·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Gang ChenShi-Ying Yu

❮ Previous
Next ❯

Related Concepts

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
R Glynne-JonesM Buyse
The American Journal of Chinese Medicine
Chong-Zhi Wang, Chun-Su Yuan
The Journal of Alternative and Complementary Medicine : Research on Paradigm, Practice, and Policy
Chong-Zhi WangChun-Su Yuan
Life Sciences
Marcy J Balunas, A Douglas Kinghorn
© 2022 Meta ULC. All rights reserved